Marina Biotech (MRNA) Reports Q4 Revenues Above Estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Moderna Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights Recent Pipeline Progress
March 6, 2019 7:00 AM ESTShows Continued Execution Across its Pipeline of Infectious Disease, Immuno-Oncology and Rare Disease Programs
Ends Year With $1.7 Billion in Cash, Cash Equivalents and Investments
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today reported financial results for the fourth quarter and full year of 2018 and highlighted pipeline progress since the Companys last corporate update in January.
New updates announced today include:... More
